{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:05:17Z","timestamp":1792886717904,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":227,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperphosphataemia is an independent risk factor for accelerated cardiovascular disease in chronic kidney disease (CKD), although the mechanism for this is poorly understood. We investigated the effects of sustained exposure to a high-phosphate environment on endothelial function in cellular and preclinical models, as well as in human subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Resistance vessels from rats and humans (\u00b1 CKD) were incubated in a normal (1.18 mM) or high (2.5 mM) phosphate concentration solution and cells were cultured in normal- (0.5 mM) or high-phosphate (3 mM) concentration media. A single-blind crossover study was performed in healthy volunteers, receiving phosphate supplements or a phosphate binder (lanthanum), and endothelial function measured was by flow-mediated dilatation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Endothelium-dependent vasodilatation was impaired when resistance vessels were exposed to high phosphate; this could be reversed in the presence of a phosphodiesterase-5-inhibitor. Vessels from patients with CKD relaxed normally when incubated in normal-phosphate conditions, suggesting that the detrimental effects of phosphate may be reversible. Exposure to high-phosphate disrupted the whole nitric oxide pathway with reduced nitric oxide and cyclic guanosine monophosphate production and total and phospho endothelial nitric oxide synthase expression. In humans, endothelial function was reduced by chronic phosphate loading independent of serum phosphate, but was associated with higher urinary phosphate excretion and serum fibroblast growth factor 23.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These directly detrimental effects of phosphate, independent of other factors in the uraemic environment, may explain the increased cardiovascular risk associated with phosphate in CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfw252","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T20:48:40Z","timestamp":1469220520000},"page":"1617-1627","source":"Crossref","is-referenced-by-count":30,"title":["Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway"],"prefix":"10.1093","volume":"32","author":[{"given":"Kathryn K","family":"Stevens","sequence":"first","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"},{"name":"2The Renal Transplant Unit, Western Infirmary, (Now based at The Queen Elizabeth University Hospital) Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Denby","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan K","family":"Patel","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"},{"name":"2The Renal Transplant Unit, Western Infirmary, (Now based at The Queen Elizabeth University Hospital) Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"},{"name":"2The Renal Transplant Unit, Western Infirmary, (Now based at The Queen Elizabeth University Hospital) Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kettlewell","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey L","family":"Smith","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J","family":"Clancy","sequence":"additional","affiliation":[{"name":"2The Renal Transplant Unit, Western Infirmary, (Now based at The Queen Elizabeth University Hospital) Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Delles","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G","family":"Jardine","sequence":"additional","affiliation":[{"name":"1BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK"},{"name":"2The Renal Transplant Unit, Western Infirmary, (Now based at The Queen Elizabeth University Hospital) Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"key":"2025102312501183900_gfw252C1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfu038","article-title":"Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study","volume":"29","author":"Betriu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501183900_gfw252C2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"(12 Suppl 3)","key":"2025102312501183900_gfw252C4","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1681\/ASN.2006080923","article-title":"Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?","volume":"17","author":"Achinger","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.med.58.071105.111123","article-title":"Kidney disease and cardiovascular risk","volume":"58","author":"Tonelli","year":"2007","journal-title":"Annu Rev Med"},{"key":"2025102312501183900_gfw252C6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025102312501183900_gfw252C7","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"(Suppl 2)","key":"2025102312501183900_gfw252C8","first-page":"ii1514","article-title":"The effects of rosuvastatin versus placebo on cardiovascular outcomes in patients with end stage renal disease on haemodialysis\u2014results of the AURORA study","volume":"2","author":"Fellstrom","year":"2009","journal-title":"NDT Plus"},{"key":"2025102312501183900_gfw252C9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"(12 Suppl)","key":"2025102312501183900_gfw252C10","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"2025102312501183900_gfw252C12","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1111\/j.1399-0012.2011.01400.x","article-title":"Serum phosphate and outcome at one year after deceased donor renal transplantation","volume":"25","author":"Stevens","year":"2011","journal-title":"Clin Transplant"},{"key":"2025102312501183900_gfw252C13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/ndt\/gfp040","article-title":"Glomerular filtration rate and serum phosphate: an inverse relationship diluted by age","volume":"24","author":"Cirillo","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501183900_gfw252C14","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/TP.0b013e31819cd122","article-title":"Elevated serum phosphate predicts mortality in renal transplant recipients","volume":"87","author":"Connolly","year":"2009","journal-title":"Transplantation"},{"key":"2025102312501183900_gfw252C15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2215\/CJN.07810910","article-title":"Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction","volume":"6","author":"Bellasi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/heartjnl-2011-300570","article-title":"Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study","volume":"98","author":"Chue","year":"2012","journal-title":"Heart"},{"key":"2025102312501183900_gfw252C17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00041552-200111000-00003","article-title":"Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis)","volume":"10","author":"Block","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025102312501183900_gfw252C18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040622311433771","article-title":"Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective","volume":"3","author":"Cozzolino","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"2025102312501183900_gfw252C19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025102312501183900_gfw252C20","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"22","author":"Voormolen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501183900_gfw252C21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"2025102312501183900_gfw252C22","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","article-title":"Relation between serum phosphate level and cardiovascular event rate in people with coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"2025102312501183900_gfw252C23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1440-1797.2012.01618.x","article-title":"Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk","volume":"17","author":"Toussaint","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"2025102312501183900_gfw252C24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1681\/ASN.2008020141","article-title":"Serum phosphorus levels associate with coronary atherosclerosis in young adults","volume":"20","author":"Foley","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/ndt\/gfv404","article-title":"Moderator's view: phosphate binders in chronic kidney disease patients: a clear \u2018No\u2019 at the moment, but stay tuned","volume":"31","author":"Zoccali","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501183900_gfw252C26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.2008.644","article-title":"The emerging role of phosphate in vascular calcification","volume":"75","author":"Giachelli","year":"2009","journal-title":"Kidney Int"},{"key":"2025102312501183900_gfw252C27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ Res"},{"key":"2025102312501183900_gfw252C28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3164\/jcbn.11-96","article-title":"Dietary phosphate restriction ameliorates endothelial dysfunction in adenine-induced kidney disease rats","volume":"51","author":"Van","year":"2012","journal-title":"J Clin Biochem Nutr"},{"key":"2025102312501183900_gfw252C29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312501183900_gfw252C30","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"2025102312501183900_gfw252C31","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"2025102312501183900_gfw252C32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1681\/ASN.2008101106","article-title":"Dietary phosphorus acutely impairs endothelial function","volume":"20","author":"Shuto","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501183900_gfw252C33","doi-asserted-by":"crossref","first-page":"e23268","DOI":"10.1371\/journal.pone.0023268","article-title":"Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability","volume":"6","author":"Peng","year":"2011","journal-title":"PLoS One"},{"key":"2025102312501183900_gfw252C34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/heart.83.2.205","article-title":"Abnormalities of endothelial function in patients with predialysis renal failure","volume":"83","author":"Thambyrajah","year":"2000","journal-title":"Heart"},{"key":"2025102312501183900_gfw252C35","first-page":"721","article-title":"Endothelial function, CRP and oxidative stress in chronic kidney disease","volume":"18","author":"Annuk","year":"2005","journal-title":"J Nephrol"},{"key":"2025102312501183900_gfw252C36","doi-asserted-by":"crossref","first-page":"H2","DOI":"10.1152\/ajpheart.00471.2010","article-title":"Assessment of flow-mediated dilation in humans: a methodological and physiological guideline","volume":"300","author":"Thijssen","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025102312501183900_gfw252C37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-7061(01)02326-3","article-title":"Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures","volume":"15","author":"Van Bortel","year":"2002","journal-title":"Am J Hypertens"},{"key":"2025102312501183900_gfw252C38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1074248409333266","article-title":"The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects","volume":"14","author":"Keswani","year":"2009","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025102312501183900_gfw252C39","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"2025102312501183900_gfw252C40","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0600031077.x","article-title":"Impaired endothelial function in isolated human uremic resistance arteries","volume":"60","author":"Morris","year":"2001","journal-title":"Kidney Int"},{"key":"2025102312501183900_gfw252C41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1479164113486662","article-title":"Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction","volume":"10","author":"Ando","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"2025102312501183900_gfw252C42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000327131","article-title":"Does uremia cause vascular dysfunction?","volume":"34","author":"Brunet","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"2025102312501183900_gfw252C43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/TP.0b013e318295852c","article-title":"Proteinuria and outcome after renal transplantation: ratios or fractions?","volume":"96","author":"Stevens","year":"2013","journal-title":"Transplantation"},{"key":"2025102312501183900_gfw252C44","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women","volume":"21","author":"Burnett","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2025102312501183900_gfw252C45","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2006-0021","article-title":"Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men","volume":"91","author":"Antoniucci","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102312501183900_gfw252C46","doi-asserted-by":"crossref","first-page":"297070","DOI":"10.4061\/2011\/297070","article-title":"Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation","volume":"2011","author":"Stevens","year":"2011","journal-title":"Int J Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/10\/1617\/24363411\/gfw252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/10\/1617\/24363411\/gfw252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:18Z","timestamp":1761238278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/10\/1617\/3059463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,7,22]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw252","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2016,7,22]]}}}